This is a summary of the European public assessment report (EPAR) for Tacforius. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Tacforius. For practical information about using Tacforius, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
Therapeutic Area (MeSH)
N/AATC Code
L04AD02
ATC Item
tacrolimus
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| tacrolimus monohydrate | N/A | Tacrolimus liposomal |
EMA Name
Tacforius
Medicine Name
Tacforius
Aliases
N/ANo risk management plan link.
